Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
研究单位：[1]Department of Hematology Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology Wuhan,Hubei,China,430030[2]CSPC Ouyi Pharmaceutical Co.,Ltd.
研究目的：
To evaluate the safety and efficacy of mitoxantrone hydrochloride liposome in combination with rituximab and lenalidomide in the treatment of relapsed and refractory diffuse large B-cell lymphoma (DLBCL).
